Table 4.

Effect of Neoadjuvant Chemotherapy on EGFR Mutation Status Before and After Treatment in Tissue Samples From Patients With Stages IIb to IIIb NSCLC (n = 63)

Prechemotherapy	Postchemotherapy				Total
	Wild Type		Mutated
	No.	%	No.	%	No.	%
Wild type	39	61.9	2	3.2	41	65.1
Mutated	12	19.0	10	15.9	22	34.9
Total	51	81.0	12	19.0	63	100.0

NOTE. P = .013 (McNemar test).

Abbreviation: NSCLC, non–small-cell lung cancer.